Introduction to Shared Decision-Making in Psychosis

The transition following a first-episode psychosis (FEP) remission represents a critical phase in psychiatric care. Clinicians and patients often face a difficult choice regarding the long-term use of pharmacotherapy. To address this, researchers have developed a new antipsychotic medication decision aid aimed at facilitating shared decision-making. This tool prioritizes recovery goals like autonomy and social reintegration, which traditional clinical models sometimes overlook. Consequently, the prototype provides a structured framework for patients to navigate the complexities of their treatment journey.

Core Sections of the Antipsychotic Medication Decision Aid

The co-developed prototype utilizes a patient-centered design informed by international standards such as IPDAS and the CHIME framework. It is structured into five essential sections: a decision overview, personal values assessment, a balanced review of risks and benefits, a planning module, and shared real-life experiences. Additionally, the tool includes visual decision exercises that help patients clarify their preferences. Therefore, this antipsychotic medication decision aid serves as more than just an information sheet; it acts as an interactive guide for deep clinical engagement.

Stakeholder Feedback and Clinical Integration

Evaluation of the prototype revealed high levels of acceptability among patient partners, caregivers, and healthcare providers. Most users described the resource as relatable and empowering. In contrast to standard care, version 3 of the tool received near-perfect scores for clarity and balance. However, some clinicians expressed concerns regarding time constraints and how to integrate such tools into a busy clinical workflow. Furthermore, while early feedback is promising, the research team emphasizes that pilot testing is necessary to evaluate the aid's impact on treatment satisfaction and long-term outcomes.

FAQs

What is the primary goal of this decision aid?

The tool aims to support individuals who have achieved remission from first-episode psychosis in making an informed choice to continue, reduce, or stop their antipsychotic medication based on their personal values and clinical evidence.

Does the tool account for the risks of stopping medication?

Yes, the decision aid includes a dedicated section on risks and benefits, providing balanced evidence regarding the potential for relapse versus the reduction of side effects.

How was this decision aid developed?

A multidisciplinary steering group, including individuals with lived experience, clinicians, and researchers, co-developed the tool using iterative feedback and international patient decision aid standards.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Béchard L et al. Development of a patient decision aid prototype on the decision to continue, reduce or discontinue antipsychotic medication following remission of first-episode psychosis. BJPsych Open. 2026 May 06. doi: 10.1192/bjo.2026.11034. PMID: 42087272.

2. World Health Organization. Duration of antipsychotic treatment in individuals with a first psychotic episode. mhGAP Guideline Update. 2023.

3. Zisman-Ilani Y et al. Usability and Feasibility of the Antipsychotic Medication Decision Aid in a Community Program for First-Episode Psychosis. Psychiatric Services. 2024;75(8):745-752.